Travere's FILSPARI earned a conversion of its accelerated approval for IgA nephropathy into a full approval, a decision that came with an expanded label
CEO Eric Dube describes the drug's mechanism, the new population, and what else Travere is working on that will have near-term catalysts.
Comments